Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Bofanglutide

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

Gan & Lee Pharmaceuticals · Phase 2 · Completed · Enrollment 326

NCT06737042

ArmPopulationDoseWeeksEstimandWeight change
24 mg GZR18 groupObesity or overweight24 mgn/rn/rn/r
36 mg GZR18 groupObesity or overweight36 mgn/rn/rn/r
48 mg GZR18 groupObesity or overweight48 mgn/rn/rn/r
Tirzepatide groupObesity or overweightn/rn/rn/rn/r